innovating novel immunotoxin antibody assets
Post on 23-Feb-2022
3 Views
Preview:
TRANSCRIPT
Company Overview
May 2021
Innovating Novel Immunotoxin Antibody Assetshttp://www.fatiabgen.com
PROPRIETARY AND CONFIDENTIAL © 2021 Fatiabgen
Not For Disclosure Or Use Without Permission.
Except for statements of historical fact, the statements in this presentation are forward-looking statements, including, but not limited to, statements
regarding the future development of our proprietary technology; These statements constitute "forward-looking statements" within the meaning of Section
27A of the Securities Act and Section 21E of the Securities Exchange Act and are usually identified by the use of words such as "anticipates,“, "believes,"
"estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "will," and variations of such words or similar expressions. These forward-
looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information
currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as
reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies
will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by
a variety of risks and factors that are beyond our control. These statements involve risks and uncertainties that can cause actual results to differ materially
from those in such forward-looking statements. Important factors that may cause actual results to differ materially from the results discussed in the forward-
looking statements include risks and uncertainties, including (1) our failure to secure and maintain relationships with collaborators; (2) risks relating to clinical
trials and other uncertainties of product candidate development; (3) risks relating to the commercialization, if any, of our proposed product candidates
(such as marketing, regulatory, product liability, supply, competition, and other risks); (4) dependence on the efforts of third parties including our strategic
partners; (5) dependence on intellectual property; and (6) risks from global pandemics including COVID-19. Existing and prospective investors are cautioned
not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. These forward-looking statements reflect
management’s current views and we do not undertake to update any of these forward-looking statements to reflect a change in events or circumstances that
occur after the date of this presentation except as required by law.
2
Disclaimer
PROPRIETARY AND CONFIDENTIAL © 2021 Fatiabgen
Not For Disclosure Or Use Without Permission.
Company Overview
Founded March 2020 Located Songpa, Seoul, Korea
Capital KRW 308 Mn (617,000 shares) Employees 11 (R&D 6 / Sales & Admin 5)
Ownership Key Management : 70% / Angel: 30% Stage Seeding stage
Market Cap KRW 9.18 Bn ($8.2 M) Status Venture Company (06/20~06/22)
3
In/Out Licensing
Biotech company using advanced cancer therapeutics
Core Technology Business Model R&D Strategy
Paper/Patent Assetization
Research/development collaborationNext Generation Recombinant Immunotoxin
Open Innovation
Unique Mode-of-Action
Develop drug delivery system against complex target cancer
Platform/Pipeline development
PROPRIETARY AND CONFIDENTIAL © 2021 Fatiabgen
Not For Disclosure Or Use Without Permission.
• Dr. Hanseok Choe currently working in Asan Hospital specialized in immunotoxin research and patents were foundation elements for Fatiabgen’s R&D
• Fatiabgen’s private market value of $8.2M after the latest funding round in August 2020
• Dr. Jungche Lim, an antibody expert, joined Fatiabgen from Y-Biologics to lead immunotoxin research.
• Joint R&D collaboration with Y-Biologics, Chunnam University, and Wonkwang university
4
Company History
2015
2018
Q1, 2021
2020. 03
2020. 08
• Dr. HanseokChoe initiated immunotoxin research from his own lab
• Dr. HanseokChoe Published several immunotoxin related papers
• Acquire immunotoxin related patents for further development
• March 2020: Establish‘Fatiabgen’ (Appoint Dr. Han seok Choe as SBA)
• Aug 2020: Capital increase by issuing new stock (Post value: $8.2M)
• Feb 2021: Appointed Jungche Lim as Vice President & CSO in Fatiabgen
• Dec 2020: Appointed JayJay Lee as CEO & Investor
• May 2020: License-in 6 Patents from Dr. Hanseok Choe
• March 2021: Appointed Gunseop Lee as CTO in Fatiabgen
Q2, 2021
• April 2021: Joint R&D with Y-Biologics: Discovery of Antibody target Pancreatic cancer
• April 2021: Joint R&D with ChunnamUniversity: Discovery of Toxin target solid cancer tumors
PROPRIETARY AND CONFIDENTIAL © 2021 FatiAbGen
Not For Disclosure Or Use Without Permission.
Fatiabgen’s people
5
PROPRIETARY AND CONFIDENTIAL © 2021 Fatiabgen
Not For Disclosure Or Use Without Permission.6
Chief Executive Office Vice President / Chief Science Officer
JayJay LeeChief Executive OfficerGlobal, Startup company expert
Over 17 years of serving Leadership position from global companies as well as startup companies with business success & growth
EducationB.A. at Yonsei University Kyunggi High School
ExperienceCountry Manager Korea / Japan : Targus LLCGlobal Senior Director : AnymodeCorporationCountry Manager Korea : Belkin International
Awards2015: Highest Performance Leader in Asia region : Targus LLC2007: Highest Net Sales Achievement in Asia region: Belkin International
Jungchae, LimVice President / Chief Science OfficerTherapeutic antibody expert
Major contribution: Responsible for research collaboration with LegoChem biosciences and Pyxis Oncology worth $294M (Upfront $9.5M)
EducationPh.D. Biochemistry, Chonnam national universityM.S. Biochemistry, Chonnam national universityB.S. Genetic engineering, Sungkyunkwan University
ExperienceChief Science Officer : Y-BiologicsVisiting Fellow: NIH, MD, USA
Awards2014: Research achievement: NIH
PROPRIETARY AND CONFIDENTIAL © 2021 Fatiabgen
Not For Disclosure Or Use Without Permission.7
Co-founder / Scientific Board Advisor Chief Technology Officer
Gunsup, LeeChief Technology Officer & PhD
Scientist participate over 30 scientific journal, owned 4 patents related to animal / DNA viruses
EducationPh.D., Department of Genetic Engineering, Sungkyunkwan University, Graduate School, Korea.Thesis : Preventive and therapeutic effects by 3D8 scFv against Herpesviridae infections on HeLa cells and C57BL/6 mice
Experience2019 – 2020 : Chief researcher (Novelgen)2016–2018: Postdoctoral fellow (NationalInstitute of Animal Science)2015 – 2016: Chief of research department(Tooth Stem Cell Bank Inc.)2011 – 2013 : Postdoctoral fellow (KoreaInstitute of Ocean Science and Technology)
Hanseok ChoeProfessor & PhD
Pioneer Immunotoxin research & development
Education• Ph.D., Physiology and Biophysics. Cornell University Weill Graduate School of Medical Sciences, New York, NY 10021, USA.• MS, Neuroscience. Seoul National University, Graduate School of Natural Science, Seoul, Korea.• BS, Molecular Biology. Seoul National University, College of Natural Science, Seoul, Korea.
Experience• Professor, University of Ulsan College of Medicine, Seoul, Korea• Postdoctoral Fellow, Department of Pharmacology Institute of Cardiovascular Research, Chonbuk National University, Chonju, Korea• Postdoctoral Fellow, The Salk Institute for Biological Studies, Structural Biology Laboratory, CA, USA• Postdoctoral Fellow, Dept. Physiology and Biophysics, Cornell University Weill Medical College, NY, USA• Research Assistant, Pohang University of Science and Technology, Pohang, Korea
PROPRIETARY AND CONFIDENTIAL © 2021 Fatiabgen
Not For Disclosure Or Use Without Permission.8
Scientific Advisor Board members
Chong-Hwan ChangCEO of MetiMedi Pharmaceuticals
Education• Ph.D., Structural Biology. University of Pittsburgh, Department of Structural Biology, USA• MS, Physical Chemistry. Seoul National University, College of Natural Science, Seoul, Korea• BS, Physical Chemistry. Seoul National University, College of Natural Science, Seoul, Korea
Dr. SANG HYUN MOH CEO/CTO of BIO-FD&C Co., Ltd
Education• Ph.D., Sungkyunkwan University SAINT, Suwon.• MS, Gwangju Institute of Science and Technology (GIST), Gwangju.• BS, Sungkyunkwan University Genetic Engineering, Suwon.
PROFESSIONAL AFFILIATE• 2014-2016 President, Antibody Society of Korea• 2013-2016 Board Member, BioConvergence• 2012-2016 Board Member, Scripps Korea Antibody Institute• 2011-2013 Board Member, Korea Drug Development Fund (KDDF)• 2010-2012 Adjunct Professor, College of Pharmacy, Seoul National University• 2006-2009 Member of the BioCluster Build up, Korean Government
Experience• Vice President, CTO Green Cross Corp.• Director, Bristol-Myers Squibb, Molecular Biosciences• Director, head of protein crystallography group. DuPont Pharmaceutical Company• Biophysicist, Argonne National Laboratory
Experience• CEO/CTO of BIO-FD&C Co., Ltd / Project Leader in Nanobioscience and Stem Cells.• Adjunct Professor, School of Global Entrepreneurship and Information Communication Technology, Handong Global University.• Outpatient Professor, College of Medicine, Chung Ang University• Director, The Asian Society of Natural Products
PROPRIETARY AND CONFIDENTIAL © 2021 Fatiabgen
Not For Disclosure Or Use Without Permission.9
R&D Collaboration Partnership - Academic
Chungoo Park, Ph.D.Professor, Chonnam National University
Education• Ph.D., Biology; Molecular Evolutionary Biology option, The Pennsylvania State University, University Park, PA, USA • M.S., Computer Science, Gwangju Institute of Science and Technology, Gwangju, Korea • B.S., Computer Science & Engineering, Inha University, Incheon, South Korea
Jae Ho Seo, Ph.D.Professor, Wonkwang University
Education• Ph.D., School of Biological Sciences and Technology, Chonnam National University, Gwangju, Korea.• M.S., Dept. of Biology, Chonnam National University, Gwangju, Korea Thesis: Radiation induced C-terminal truncation of mouse pancreatic Prx II • B.S., Dept. of Biological Sciences, Chonnam National University, Gwangju, Korea
PROFESSIONAL AFFILIATE• Postdoctoral IRTA Fellow, Program in Genomics of Differentiation, National Institute of Child Health and Human Development, National Institutes of Health• Postdoctoral Research Fellow, Department of Ecology and Evolutionary Biology, University of Michigan
Publications (Journal)• Comparability of reference-based and reference-free transcriptome analysis approaches at the gene expression level. BMC Bioinformatics (2020) (in press)• Paralogs and Isoforms Classifier based on Machine-learning approaches. BMC Bioinformatics. (2020) (in press)• Lipocalin2 Induced by Bacterial Flagellin Protects Mice against Cyclophosphamide Mediated Neutropenic Sepsis. Microorganisms. (2020) 8(5): 646• Identification of Differentially Expressed Genes Associated with Extracellular Matrix Degradation and Inflammatory regulation in Calcific Tendinopathy using RNA Sequencing. Calcified Tissue International. (2020)
PROFESSIONAL AFFILIATE• Research Professor, Hypoxia-related Disease Research Center, College of Medicine, InhaUniversity, Incheon, Korea• Associate Staff Scientist, Wistar Institute, Philadelphia, PA, USA• Postdoc Fellow, Wistar Institute, Philadelphia, PA, USA• Postdoc Fellow, Winship Cancer Institute in Emory University, Atlanta, GA, USA • Visiting Research, Lab of Biochemistry/NHLBI/NIH, Bethesda, MD, USA
Publications (Journal)• The mitophagy effector FUNDC1 controls mitochondrial reprogramming and cellular plasticity in cancer cells. Sci signal. 2020,13(642): eaaz8240• Latifolin inhibits oxidative stress-induced senescence via upregulation of SIRT1 in human dermal fibroblasts. Biol Pharm Bull. 2020,43(7): 1104-1110• Mitochondrial fission factor is a novel Myc-dependent regulator of mitochondrial permeability in cancer. EBioMedicine. (* These authors are contributed equally) 2019, 48: 353-363.• Myc-mediated transcriptional regulation of the mitochondrial chaperone TRAP1 controls primary and metastatic tumor growth. J Biol Chem. 2019, 294(27): 10407-10414
PROPRIETARY AND CONFIDENTIAL © 2021 Fatiabgen
Not For Disclosure Or Use Without Permission.
PROPRIETARY AND CONFIDENTIAL © 2021 Fatiabgen
Not For Disclosure Or Use Without Permission.
Market Landscape – ADC / Immunotoxin
10
PROPRIETARY AND CONFIDENTIAL © 2021 Fatiabgen
Not For Disclosure Or Use Without Permission.
• Global ADC market is expected to reach $13.6 bn in 2025, compared with $2.6 bn in 2019 CAGR of 31.6%
• Up to date, total of 10 ADCs have been approved by the FDA. 7 ADCs approved after 2017.
• More than 80 ADCs undergoing clinical trials as of June 2020
11
Antibody-Drug Conjugates(ADC) Market Landscape
Drug Maker Condition Trade nameApproval
Year
Annual Revenue
Forecast
Gemtuzumab ozogamicin Pfizer/Wyeth relapsed acute myelogenous leukemia (AML) Mylotarg 2017;2000 N/A
Brentuximab vedotinSeattle Genetics,
Millennium/Takedarelapsed HL and relapsed sALCL Adcetris 2011 Over $1B
Trastuzumab emtansineGenentech,
RocheHER2-positive metastatic breast cancer (mBC) following treatment with trastuzumab and a maytansinoid. First solid tumor treatment.
Kadcyla 2013 $1.4B (2019)
Inotuzumab ozogamicin Pfizer/Wyeth relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia Besponsa 2017 Potential $2B
Polatuzumab vedotin-piiq Genentech, Roche relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) Polivy 2019 $56M
Enfortumab vedotinAstellas
/Seattle Geneticsadult patients with locally advanced or metastatic urothelial cancer who have received a PD-1 or PD-L1 inhibitor, and a Pt-containing therapy
Padcev 2019 Est $250M (2020)
Trastuzumab deruxtecanAstraZeneca
/Daiichi Sankyoadult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens
Enhertu 2019 $336M (2020)
Sacituzumab govitecan Immunomedicsadult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for patients with relapsed or refractory metastatic disease
Trodelvy 2020 Est $100M
Belantamab mafodotin-blmf GlaxoSmithKline (GSK) adult patients with relapsed or refractory multiple myeloma Blenrep 2020 Potential $1.6B
$2.6 bn
$13.6 bn
2019 2025< Lists of ADCs drugs have been approved by the FDA >
PROPRIETARY AND CONFIDENTIAL © 2021 Fatiabgen
Not For Disclosure Or Use Without Permission.
• The global Immunotoxin Drug Market was valued at $1.62 billion in 2020 and is forecasted togrow at 9.6% CAGR between 2020 and 2026, culminating in 2026 global sales of $2.78 billion.
• To date, a total of 3 RITs have been approved by the FDA, including Denileukin diftitox (Ontak),tagraxofusp-erzs (ElzonrisTM), Moxetumomab pasudotox (LumoxitiTM)
• More than 60 immunotoxins are currently undergoing pre-clinical and clinical testing (Amani etal., 2020).
12
Immunotoxin : An emerging approach for a wide variety of cancer treatment
Name Company Format FDA approval Indication
OntakDenileukin diftitox
Eisai Corporation DAB389-IL2 1999 Cutaneous T-cell lymphoma
ElzonrisTagraxofusp-erzs
Stemline Therapeutics DAB-IL3 2018Blastic plasmacytoid dendritic cell neoplasm
LumoxitiMoxetumomab
AstraZeneca Anti-CD22 sdFv-PE38 2018 Hairy cell leukemia
ViciniumOportuzumab Monatox
Sesen BioAnti-EpCAM scFv-PE38
(Humanized Ab)
2020FDA Acceptance and P
riority Review
Non-muscle-invasive bladder cancer
$1.622m$2.116m
$2.795 m
2020 2023 2026
< Lists of Immunotoxin drugs have been approved by the FDA >
PROPRIETARY AND CONFIDENTIAL © 2021 Fatiabgen
Not For Disclosure Or Use Without Permission.
• RIT has relative merits over Antibody Drug Conjugates, huge potential for the treatment of various cancer types
13
Comparison: ADC (Antibody Drug Conjugate) vs RIT (Recombinant Immunotoxin)
ADC: RIT:
ADC RIT Advantage
Key technology Conjugation, payload Translocation domain, Toxin Expandable toward drug delivery
Payload Chemical Bacterial, plant, marine proteinDrug manufacturing with recombinant DNA technology
Mechanism of action (MoA)Most commonly antitubulin agents,
lysosome requiredProtein synthesis inhibition,
No lysosome requiredTargeting intracellular receptors, cytosolic proteins, and cell organelles
Toxicitymost commonly peripheral neuropathy,
myelosuppressionVascular leak syndrome Ways to reduce toxicity are possible
Bystander effect Yes None No off-target toxicity
Target cell killing Mostly dividing cells Dividing and non-dividing cells Massive killing effect
MoA against standard chemotherapy
Overlapping Non-overlappingCombination therapy with chemotherapy is possible
No. of FDA approved drugs 10 3
PROPRIETARY AND CONFIDENTIAL © 2021 Fatiabgen
Not For Disclosure Or Use Without Permission.
PROPRIETARY AND CONFIDENTIAL © 2021 Fatiabgen
Not For Disclosure Or Use Without Permission.
OPTIMIZE IMMUNOTOXIN RESEARCH & DEVELOPMENT
Fatiabgen’s Core Assets
14
PROPRIETARY AND CONFIDENTIAL © 2021 Fatiabgen
Not For Disclosure Or Use Without Permission.
Fatiabgen has secured 6 issued patents, seeds for immunotoxin development
15
IP Portfolio
No Classification Title of Invention Registration No./Date
1
Protein Expression & Purification
Expression and purification method of biological active human FGF2 with human PDIb´a´ domain in Escherichia coli 10-1434734 (2014.08.20)
2 Soluble expression and purification method of active recombinant human Dkk2 10-1508052 (2015.03.26)
3 Soluble expression and purification method of active recombinant human CCL2 10-1508056 (2015.03.26)
4Growth FactorExpression & Purification
Expression Vector for Human Erythropoietin and Process for Production of Erythropoietin Using Thereof 10-1364864 (2014.12.12)
5 Expression and purification method of biologically active human LIF with human PDIb´a´ tag in Escherichia coli 10-1434739 (2014.08.20)
6
Protein Expression & Purification
Soluble overexpression and purification method of biological active recombinant human EC-SOD in Escherichia coli 10-1429342 (2014.08.05)
PROPRIETARY AND CONFIDENTIAL © 2021 Fatiabgen
Not For Disclosure Or Use Without Permission.
• Fatiabgen has various monoclonal antibodies specifically recognizing their targets.
16
Fatiabgen Assets: Monoclonal antibody library
Antibody collectionTarget
Antigen Antibody Antigen Antibody
CEA
2xNb4
Mesothelin
Nb02
Nb2 Nb11
Nb4.1 Nb18
Nb4 Nb24
Nb9 scFv
scFv
Mucin1
Nb1
HER2Nb17 Nb2
scFv Nb3
HGFRNb1
PSMA
Nb
scFv Nb2
EpCAMNb20 Nb3
scFv scFv
Frizzled7
NbGlypican3
Nb9
Nb2 scFv
Nb3
• Highly expression in cancer cells vs normal cells
• Clinicopathological relevance
• No or limited shedding
• Internalization capability
[Target selection criteria]
Target Indication
CEA Cholangiocarcinoma, colon, gastric cancer
HER2 Breast, pancreatic cancer
HGFR Cholangiocarcinoma, lung, gastric cancer
EpCAMCholangiocarcinoma, lung, breast, prostate, pancreatic, gastric cancer
Frizzled7 Hepatocellular carcinoma, gastric, breast, colon cancer
Mesothelin Mesothelioma, pancreatic cancer, ovarian cancer
Mucin1 Lung, pancreatic cancer
PSMA Prostate, pancreatic cancer
Glypican3 CholangiocarcinomaNb: Single domain antibody, scFv: Single chain variable fragment
[Consideration] Size, valencies, flexibility, epitope, PK
PROPRIETARY AND CONFIDENTIAL © 2021 Fatiabgen
Not For Disclosure Or Use Without Permission.
• Fatiabgen has investigated cell killing effects of various immunotoxins on cancer cells
17
Fatiabgen Assets: Immunotoxin library
Target-concentration dependent cell killing effectToxin
Classification toxin
Bacterial toxin Pseudomonas toxin, diphtheria toxin, shiga toxin
Mycotoxin Fungal toxins
Marine toxin Algae toxins
Phytotoxin Plant toxins including ricin
Venomes from land
animalsVenomes containing crotamine
• Cytotoxic substances naturally produced by living organisms(bacteria, fungus, plant, and animal)
• Appear in sizes ranging from small molecules to large proteins, and have diverse mechanisms of action
• Only small quantities of toxins damage cells
[Description][PE24]
[Crotamine]
• Cytolethal molecule to genetically attached to a targeting moiety • Strong cytotoxicity with low toxicity• Low immunogenicity
[Therapeutic application]
[Classification]
PROPRIETARY AND CONFIDENTIAL © 2021 Fatiabgen
Not For Disclosure Or Use Without Permission.
• Fatiabgen has secured protein expression system for process development advantage and high bioavailability
Fatiabgen Assets: Increased Solubility
18
High solubility and purity Solubilization test
[Protein expression with chaperone proteins]
M: MarkerC: CrudeI: Induction
P: PrecipitateS: Soluble
Induction at 37oC
[Protein expression with different competent cells]
Induction at 18oC
Induction at 37oC Induction at 18oC
Cultivation in E.coli BL21 (DE3)MBP-anti CEA (scFv)-PE24
1st ColumnMBP-affinity chromatography
Cleavage by TEV protease
2nd ColumnHis-affinity chromatography
Quantification
M
M: MarkerTEV: TEV cleavageAF: Affinity chromatography
[Protein purification]kDa
[Process]
Cloning Transformation in E.coli
Sequencing Induction
Competent cell selection
Chaperone selection
Protein purification
Cell disruptionChromatography
Solubility check
Cell lysates
18
PROPRIETARY AND CONFIDENTIAL © 2021 Fatiabgen
Not For Disclosure Or Use Without Permission.
PROPRIETARY AND CONFIDENTIAL © 2021 Fatiabgen
Not For Disclosure Or Use Without Permission.
Fatiabgen’s Pipeline Roadmap & Expenditure plan
19
PROPRIETARY AND CONFIDENTIAL © 2021 Fatiabgen
Not For Disclosure Or Use Without Permission.
• Fatiabgen’s growth strategy is to build the pipelines as well as develop platform technology
• Fatiabgen’s 3-year plan is to bring out key candidates for pre-clinical phase
• Collaborate with Y-Biologics to create novel candidates for Mesothelioma and Pancreatic cancer
20
Fatiabgen Pipeline Roadmap
Pipeline Indication Collaboration
Discovery
Preclinical Phase I Phase II Phase IIILead Selection Lead to Candidate
mAb screeningmAb
characterizationIn vitro/In vivo
PoCAb format
optimizationDrug deliveryoptimization
Toxin modification
FabG1-2139
Mesothelioma orPancreatic cancer
Y-Biologics
FabG1-3919
Small cell lung cancer In-House
FabT1-4290
Solid tumors in TME In-House
FabN1 Undisclosed In-House
Series B
2021 2022 ~ 20232024
~ 2025
Series A Series C
Beyond 2025
PROPRIETARY AND CONFIDENTIAL © 2021 Fatiabgen
Not For Disclosure Or Use Without Permission.21
Expenditure Plan (2021 ~ 2025)
Fiscal Year Investment Plan Stage InvestorSeed
AmountPre-Valuation
3Q 2021 Establish additional R&D center in Daejeon
Stage A
Investment Bank /
Venture Capital
$5M $50M
2Q~4Q 2021 Talent Acquisition - Scientists & Researchers
2021-3Q~
2023
Research & Development• Pipeline Generation- mAb screening- PoC of recombinant immunotoxin in vitro, in vivo study• Platform Development- Drug delivery optimization- Toxin modification
Global Pharma
2024 ~ 2025
Preclinical study- Cell line development- Upstream/downstream process development- Chemistry, manufacturing and control (CMC) - GLP-tox- Formulation- GMP DS and DP production- IND filing
Stage B
IB/VC
$30M $150MPharma
Others
2026 Clinical study Series C N/A TBD TBD
PROPRIETARY AND CONFIDENTIAL © 2021 Fatiabgen
Not For Disclosure Or Use Without Permission.2222
Expenditure Plan (2021 ~ 2023)
Category Item No. Investment ($) Purpose Year
Set-up/Recruiting2nd Laboratory Set-up $100K R&D Center Set-up 2021
Talent Acquisition 10 ~ 15 $1.5Mn Labor Costs 2021 ~ 2022
R&D Platform/Pipeline Generation $2.5Mn Research & Development 2021 ~ 2023
Lab Equipment
IncuCyte 1 $250K Cell-based Assay 2021
Flow Cytometer 1 $150K Target expression, Antibody specificity 2021
Confocal microscopy 1 $500K Mode-of-Action study 2022
[IncuCyte] [Flow Cytometer] [Confocal Microscopy]
PROPRIETARY AND CONFIDENTIAL © 2021 Fatiabgen
Not For Disclosure Or Use Without Permission.23
Fatiabgen R&D collaboration with world class partners
Antibody
• Research collaboration
- Screening the best mAb
- Act on the right target in the right place
• Drug engineering
- High stability in blood
- Drug delivery into the cytosol
Linker
• Building toxin library- Dr. Chun-Gu Park
• Organelle targeting- Dr. Jae-Ho Seo
Cytolytic toxin
• Providing Proof-of-Concept of drugs for clinical trial
• Exploiting competitive advantages of our drugs over competitor’s
• Getting rid of risk factors and increasing the success rate in development
• Providing the information on the scientific clues for clinical trial design
Research strategy
• Out-Licensing
• In-house development
Innovative drug development
PROPRIETARY AND CONFIDENTIAL © 2021 Fatiabgen
Not For Disclosure Or Use Without Permission.
PROPRIETARY AND CONFIDENTIAL © 2021 Fatiabgen
Not For Disclosure Or Use Without Permission.
Investment Trend – Antibody Drug Conjugates
24
PROPRIETARY AND CONFIDENTIAL © 2021 Fatiabgen
Not For Disclosure Or Use Without Permission.
• Most active investors by Stage in Antibody Drug Conjugates Market
• ADC M&A deals totaled $11.7B (16% of total disclosed biotech M&A)
• 19 IPOs up an average of 67% compared with the year 2019
25
Active Investors - ADC
Copyright 2019, Tracxn Technologies. All rights reserved
PROPRIETARY AND CONFIDENTIAL © 2021 Fatiabgen
Not For Disclosure Or Use Without Permission.
• Comparison of Total Funding raised by top companies in ADC Market
26
Comparison: Total Funding and Founded Year
Copyright 2019, Tracxn Technologies. All rights reserved
PROPRIETARY AND CONFIDENTIAL © 2021 Fatiabgen
Not For Disclosure Or Use Without Permission.
• Immunotoxin market leader, Molecular Templates (MTEM), is a clinical-stage biotech company that engages in the discovery, development, and commercialization of biologic therapeutics for the treatment of cancers.
27
Competitor Comparison
Category Molecular Templates (MTEM) Fatiabgen
Types of oncology Immunotoxin Immunotoxin
Establishment / Market Capital
2001 / $700Mn (Nasdaq) 2020 / $8.2Mn (pre-seeding)
Key investor Excel Venture, Aju IB, Sante Ventures, Longitude capital Seed stage
Revenue $18.85Mn None
Pipelines / Target
• MT-3724 / DLBCL (CD20)• MT-5111 / Multiple solid tumors (HER2)• TAK-169 / Multiple Myeloma (CD38)• MT-6402 / Solid tumors (PD-L1)
• FabG1-2139 / Mesothelioma & Pancreatic cancers • FabG1-3919 / SCLC• FabT1-4290 / TME• FabN1 / Nondisclosure
Key Technologies• Engineered version of Shiga-like Toxin A subunit• Ribosome inactivation + forced internalization + de-
immunization
• Conditional human antibody + deimmunized PE24• Novel mechanism of action to destroy cancer cells
using drug delivery• Proprietary toxin library
Location Austin, Texas Seoul, Korea
28
top related